Long-term Outcomes of Penetrating Keratoplasty in Chronic and Delayed Mustard Gas Keratitis
Overview
Authors
Affiliations
Purpose: To report the long-term outcomes of penetrating keratoplasty (PKP) in war victims with chronic and delayed mustard gas keratitis.
Methods: This noncomparative interventional case series includes patients with advanced chronic or delayed mustard gas keratitis who had undergone PKP from 1989 to 2006. Best-corrected visual acuity (BCVA), graft clarity, episodes of graft rejection, duration of steroid use, and complications were evaluated. Histopathologic features of excised corneal buttons were also evaluated.
Results: Overall, 22 eyes of 19 patients underwent PKP. Mean age at the time of surgery was 41 +/- 4.6 years (range, 36-54 years), and mean follow-up duration was 40.9 +/- 48 months (range, 4-204 months). The graft remained clear in 17 (77.3%) eyes and failed in 5 (22.7%) eyes. Overall, 13 (59.1%) eyes experienced episodes of endothelial rejection, and 5 (22.7%) eyes had subepithelial immune rejection, 4 of which had simultaneous endothelial rejection. Fifteen (68.2%) eyes received topical steroids for >6 months. Fourteen (63.6%) eyes developed cataracts, leading to cataract extraction in 7 eyes. One eye developed steroid-induced glaucoma after multiple episodes of endothelial graft rejections. Mean preoperative BCVA was 1.92 +/- 0.63 logMAR, which improved to 1.04 +/- 0.65 logMAR (20/200) overall and 0.8 +/- 0.3 logMAR (20/120) in eyes with clear grafts (P < 0.001). Main histopathologic features of excised corneal buttons included corneal thinning and ulceration, loss of keratocytes, acute and chronic inflammation, stromal vascularization, and degenerative sequelae of long-standing inflammation.
Conclusions: PKP in chronic or delayed-onset mustard gas keratitis should be considered as a high-risk graft; however, with appropriate management, graft clarity and visual outcomes may be favorable.
Poudel S, Kaffash E, Zhao L, Pangeni R, Chow W, Xu Q Exp Eye Res. 2024; 243:109902.
PMID: 38641196 PMC: 11184523. DOI: 10.1016/j.exer.2024.109902.
Ophthalmic manifestations and management considerations for emerging chemical threats.
Menke B, Ryu C, Justin G, Chundury R, Hayek B, Debiec M Front Toxicol. 2023; 5:1281041.
PMID: 37941806 PMC: 10629503. DOI: 10.3389/ftox.2023.1281041.
Alemi H, Dehghani S, Forouzanfar K, Surico P, Narimatsu A, Musayeva A Exp Eye Res. 2023; 236:109657.
PMID: 37722586 PMC: 11583460. DOI: 10.1016/j.exer.2023.109657.
Ophthalmic Complications and Managements of Sulfur Mustard Exposure: A Narrative Review.
Ghavami Shahri S, Balali-Mood M, Heidarzadeh H, Abrishami M Arch Iran Med. 2023; 25(9):647-657.
PMID: 37543890 PMC: 10685765. DOI: 10.34172/aim.2022.100.
Progress towards a standardized model of ocular sulfur mustard injury for therapeutic testing.
McNutt P Exp Eye Res. 2023; 228:109395.
PMID: 36731603 PMC: 9975063. DOI: 10.1016/j.exer.2023.109395.